Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure Drugs: Inotropic Agents

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure IV: Classification and Diagnostic Evaluation

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Neurometabolic Features of Takotsubo Syndrome: A Brain <sup>18</sup>F-FDG PET Case Control-Prospective Study.

JACC. Cardiovascular imaging·2024

Same author

Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction.

Clinics and practice·2023

Same author

Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience.

Clinics and practice·2023

Same author

Atrial paced rhythm and heart rate-dependent worsening of left atrial and ventricular function.

Pacing and clinical electrophysiology : PACE·2023

Same author

Relationship between the strain measures of left atrial function and heart failure worsening.

Echocardiography (Mount Kisco, N.Y.)·2023

Same author

Impact of intra-aortic balloon counterpulsation on all-cause mortality among patients with Takotsubo syndrome complicated by cardiogenic shock: results from the German-Italian-Spanish (GEIST) registry.

European heart journal open·2023

Search research articles

Related Experiment Video

Updated: May 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Statins in Heart Failure.

Michele Correale¹, Silvia Abruzzese, Carmen Adriana Greco

¹Department of Cardiology, University of Foggia, Viale Pinto 1, 71100 Foggia, Italy. nd.brunetti@unifg.it.

Current Vascular Pharmacology

|September 29, 2012

Summary

This summary is machine-generated.

Statins significantly reduce cardiovascular events and mortality. This review explores their role in preventing heart failure (HF) for patients with coronary artery disease, summarizing key evidence.

Related Experiment Videos

Last Updated: May 18, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

Cardiology
Pharmacology

Background:

Statins are proven to reduce cardiovascular morbidity and mortality in primary and secondary prevention.
Evidence suggests statins can prevent acute coronary syndromes.
Statins may also play a role in preventing heart failure (HF).

Purpose of the Study:

To review the experimental and clinical evidence on statin therapy in heart failure management.
To consolidate current understanding of statins' impact on HF.
To assess the efficacy of statins in HF prevention and treatment.

Main Methods:

Literature review of experimental studies.
Analysis of clinical trial data.
Synthesis of evidence on statins and heart failure.

Main Results:

Statins demonstrate a significant reduction in cardiovascular events.
Studies indicate statins' efficacy in preventing acute coronary syndromes.
Evidence supports statins' potential in preventing heart failure in specific patient groups.

Conclusions:

Statins are crucial for cardiovascular event reduction.
Statins show promise in preventing heart failure in patients with coronary artery disease.
Further research confirms the multifaceted role of statins in cardiovascular health management.